Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Barrett Esophagus 1

Interventions

YF 476 2Specimen Handling 2Aspirin 2obeticholic acid 1Ursodeoxycholic Acid 1Sunitinib 1Spectrum Analysis 1Radiofrequency Ablation 1Proflavine 1Photochemotherapy 1Metformin 1Itraconazole 1Gastroscopy 1Esomeprazole 1Endoscopy, Digestive System 1Endoscopy 1Endoscopic Mucosal Resection 1Dihematoporphyrin Ether 1Dexlansoprazole 1Cetuximab 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Barrett Esophagus × Dexlansoprazole × Clear all
NCT02162758 2017-05-11

Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation

Takeda

Phase 2 Terminated
6 enrolled 19 charts
Gastrointestinal

Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡